microRNA‑99a inhibits cell proliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer

Wu,Deyao; Zhou,Yunfeng; Pan,Huixing; Qu,Ping; Zhou,Jian

doi:10.3892/mmr.2014.2792

microRNA‑99a inhibits cell proliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer

Authors:
- Deyao Wu
- Yunfeng Zhou
- Huixing Pan
- Ping Qu
- Jian Zhou
View Affiliations

Affiliations: Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City First People's Hospital, Yancheng, Jiangsu 224001, P.R. China
Published online on: October 27, 2014 https://doi.org/10.3892/mmr.2014.2792
Pages: 1469-1475

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNA‑99a (miR‑99a) was reported to be among the most frequently downregulated miRNAs in numerous types of human cancers, including prostate, bladder, hepatocellular and ovarian carcinoma, squamous cell carcinoma of the tongue, squamous cell lung carcinoma as well as childhood adrenocortical tumors. The aim of the present study was to determine the effects of miRNA‑99a on cell proliferation, colony formation ability, migration and invasion in prostate cancer. Following transfection with miRNA‑99a, cell viability, colony formation, cell migration and cell invasion assays were performed on prostate cancer cell lines, as well as western blot analysis and luciferase assays. miRNA‑99a inhibited cell proliferation, colony formation ability, migration and invasion in DU145 and PC‑3 cells, therefore indicating that miRNA‑99a may have a tumor suppressive role in prostate cancer. In addition, the present study provided the first evidence that the mechanism of action of miRNA‑99a may proceed by directly targeting fibroblast growth factor receptor 3 in prostate cancer. In conclusion, the results of the present study suggested that miRNA‑99a may have potential use as a therapeutic target for the treatment of prostate cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	McGoldrick CA, Jiang YL, Paromov V, Brannon M, Krishnan K and Stone WL: Identification of oxidized protein hydrolase as a potential prodrug target in prostate cancer. BMC Cancer. 14:772014. View Article : Google Scholar : PubMed/NCBI
3	Damber JE and Aus G: Prostate cancer. Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
4	Shavers VL, Underwood W and Moser RP: Race/ethnicity and the perception of the risk of developing prostate cancer. Am J Prev Med. 37:64–67. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ma S, Chan YP, Kwan PS, et al: MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 71:583–592. 2011. View Article : Google Scholar : PubMed/NCBI
6	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
9	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
10	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nature Rev Cancer. 6:259–269. 2006. View Article : Google Scholar
11	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
12	Schaefer A, Stephan C, Busch J, Yousef GM and Jung K: Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol. 7:286–297. 2010. View Article : Google Scholar : PubMed/NCBI
13	Fendler A, Jung M, Stephan C, et al: miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol. 39:1183–1192. 2011.PubMed/NCBI
14	Schaefer A, Jung M, Kristiansen G, et al: MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol. 28:4–13. 2010. View Article : Google Scholar
15	Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou J: MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 47:423–432. 2013. View Article : Google Scholar
16	Ventura A and Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell. 136:586–591. 2009. View Article : Google Scholar : PubMed/NCBI
17	Cui L, Zhou H, Zhao H, et al: MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer. 12:5462012. View Article : Google Scholar : PubMed/NCBI
18	Sun D, Lee YS, Malhotra A, et al: miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res. 71:1313–1324. 2011. View Article : Google Scholar : PubMed/NCBI
19	Lerman G, Avivi C, Mardoukh C, et al: MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PloS One. 6:e209162011. View Article : Google Scholar : PubMed/NCBI
20	Sun J, Chen Z, Tan X, et al: MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med Oncol. 30:4112013. View Article : Google Scholar : PubMed/NCBI
21	Nagayama K, Kohno T, Sato M, Arai Y, Minna JD and Yokota J: Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer. 46:1000–1010. 2007. View Article : Google Scholar : PubMed/NCBI
22	Li XJ, Luo XQ, Han BW, Duan FT, Wei PP and Chen YQ: MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer. 109:2189–2198. 2013. View Article : Google Scholar : PubMed/NCBI
23	Li D, Liu X, Lin L, et al: MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
24	Johnson DE and Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 60:1–41. 1993. View Article : Google Scholar : PubMed/NCBI
25	Kwabi-Addo B, Ropiquet F, Giri D and Ittmann M: Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate. 46:163–172. 2001. View Article : Google Scholar : PubMed/NCBI
26	Lafitte M, Moranvillier I, Garcia S, et al: FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Mol Cancer. 12:832013. View Article : Google Scholar : PubMed/NCBI
27	Dorkin TJ, Robinson MC, Marsh C, Neal DE and Leung HY: aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol. 189:564–569. 1999. View Article : Google Scholar
28	Azab AK, Azab F, Quang P, et al: FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 17:4389–4399. 2011. View Article : Google Scholar : PubMed/NCBI
29	Wesche J, Haglund K and Haugsten EM: Fibroblast growth factors and their receptors in cancer. BiochemJ. 437:199–213. 2011. View Article : Google Scholar
30	Ettelaie C, Fountain D, Collier ME, Elkeeb AM, Xiao YP and Maraveyas A: Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB. Biochim Biophys Acta. 1812:1591–1600. 2011. View Article : Google Scholar : PubMed/NCBI
31	Lungu G, Covaleda L, Mendes O, Martini-Stoica H and Stoica G: FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappaB and activating protein-1. Mol Carcinog. 47:424–435. 2008. View Article : Google Scholar
32	Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: ‘one size does not fit all’. Oncogene. 30:1615–1630. 2011. View Article : Google Scholar :
33	Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012.PubMed/NCBI
34	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
35	Tomlinson DC, Hurst CD and Knowles MA: Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 26:5889–5899. 2007. View Article : Google Scholar : PubMed/NCBI
36	Hernández S, de Muga S, Agell L, et al: FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol. 22:848–856. 2009.PubMed/NCBI
37	Hernández S, López-Knowles E, Lloreta J, et al: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 24:3664–3671. 2006. View Article : Google Scholar : PubMed/NCBI
38	Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN and Leung HY: Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer. 92:320–327. 2005.PubMed/NCBI